Citi reiterates Buy rating on Zenas Biopharma stock with $27 price target

Zenas Biopharma (ZBIO) is garnering significant analyst attention, with Citi reiterating a Buy rating and $27 price target, and Morgan Stanley initiating coverage with an Overweight rating and $31 price target. The positive outlook is centered on its lead drug candidate, obexelimab, targeting B cell-linked autoimmune diseases like IgG4-RD, multiple sclerosis, and SLE. Key catalysts include anticipated Phase 2 multiple sclerosis data and Phase 3 IgG4-RD results by late 2025, with additional Phase 2 SLE data expected mid-2026. The company reports a cash runway into Q4 2026 and its shares have gained over 29% in the past six months, reflecting strong market momentum ahead of these critical clinical readouts.

Analysis

Zenas Biopharma (ZBIO) is experiencing a significant increase in positive analyst coverage, centered on its lead drug candidate, obexelimab. Both Citi and Morgan Stanley have issued favorable ratings, with Citi reiterating a 'Buy' at a $27 price target and Morgan Stanley initiating with an 'Overweight' and a $31 target. The bullish sentiment is underpinned by obexelimab's potential as a differentiated therapy for B cell-linked autoimmune diseases, with specific attention on its ongoing trials for IgG4-RD, multiple sclerosis (MS), and SLE. The company's financial position appears robust, with a stated cash runway extending into the fourth quarter of 2026, which sufficiently covers the timeline for several critical data readouts. Key upcoming catalysts that will likely drive valuation are the Phase 3 IgG4-RD and Phase 2 MS results expected by year-end 2025, followed by Phase 2 SLE data in mid-2026. The stock has already demonstrated strong momentum, gaining over 29% in the past six months, reflecting growing investor confidence ahead of these pivotal clinical milestones.

Key Decisions for Investors

• Investors should view Zenas Biopharma as a catalyst-driven biotech play, with performance highly leveraged to the clinical trial readouts for IgG4-RD and multiple sclerosis expected by the end of 2025.
• The company's reported cash runway through Q4 2026 is a significant de-risking factor, as it mitigates the immediate threat of dilutive financing ahead of key data releases.
• While analyst price targets suggest substantial upside, investors must weigh this against the inherent binary risk of clinical-stage drug development, where trial outcomes will be the primary determinant of value.
• Monitor for potential business development activities over the next 12-18 months, as management has indicated this possibility, which could provide additional catalysts outside of clinical data.